Particularly since 2009, the introduction of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) has significantly transformed diabetes care in Japan (Fig. 1) [1]. This evidence concerns the gene GLP1R and diabetes mellitus.